NCT04492410: NEOSCREENCOVID

COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID)

Completed NA Last updated 30 September 2025

What this trial tests

NA trial testing rapid serological test in Cancer in 214 participants. Completed in 12 November 2021.

Timeline

21 July 2020

Primary endpoint
12 May 2021

12 November 2021

Quick facts

Lead sponsor	Centre Antoine Lacassagne
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	214
Start date	21 July 2020
Primary completion	12 May 2021
Estimated completion	12 November 2021
Sites	1 location across France

Drugs / interventions tested

• rapid serological test

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

Centre Antoine Lacassagne — full company profile →

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since December 2019, outbreak of COVID-19 caused by a novel virus SARS-Cov-2 has spread rapidly around the world and became a pandemic issue. Cancer patients seem to be at higher risk of infection and evolution to severe forms related to immunosuppression, according to the first published data from Chinese experience. However, the role of confounding factors such as age and smoking habits cannot be independently assessed. Supplementary data from a large retrospective Italian cohort suggest that the proportion of cancer patients with severe form of COVID-19 could be lower than expected. In addition, the proportion of asymptomatic SARS-Cov-2 infected cancer patients is unknown. Based on academic and expert's recommendations, most of cancer units have already modified cancer treatment during the pandemic, in order to limit the number of outpatient visits / inpatient admissions and then reduce or avoid cross infection of COVID-19, although the negative impact on patient's outcome (cancer recurrence or mortality) has not been established. Thus, a large screening for SARS-Cov-2 infection in treated cancer patients could help to: - Define an accurate prevalence of COVID-19 immunization in this population - Aggregate data on the relationship between clinical characteristics in cancer patients and COVID-19 risk. - Provide information about asymptomatic COVID-19 cases. - Organize effectively cancer units to separate infected and non-infected patients.

The RT-PCR gold-standard test for COVID-19 on nasal and pharyngeal swabs has limitations, as the test is not universally available, turnaround times can be lengthy, and reported sensitivities vary. It does not provide information about immunization status. Serological assays may be important for understanding the epidemiology of emerging SARS-Cov-2, including the burden and role of asymptomatic infections. Thus, the development of new devices or techniques for accurate diagnosis of SARS-CoV-2 infections, of fast and safe use, that could be spread in the local hospitals and clinics, would be a major advance for identifying and treating patients. In addition, information about the immunization of fragile people, such as cancer patients, could help to plan a safe strategy for anti-cancer treatment schedule and for the end of quarantine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid.
   Contu S, Schiappa R, Chateau Y, Chamorey E. · · 2025 · PMID 39830586 · DOI 10.1177/20420986241299567